Halozyme Therapeutics Inc (NASDAQ:HALO) announced on Friday that Dutch immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) has received European Commission approval for VYVGART 1000mg (efgartigimod alfa) developed with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and the first novel mechanism of action for CIDP treatment in more than 30 years.
The Commission's decision was based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date.
The approval is valid in all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval